Lung Delivery of Nicotine for Smoking Cessation

Authored by: Hui Wang , Nazrul Islam

Handbook of Lung Targeted Drug Delivery Systems

Print publication date:  October  2021
Online publication date:  October  2021

Print ISBN: 9780367490676
eBook ISBN: 9781003046547
Adobe ISBN:


 Download Chapter



Smoking-related health problems are one of the leading causes of deaths worldwide, causing a serious threat and tremendous economic burden to public health. Currently, varenicline and nicotine replacement therapies (NRTs) in the forms of nicotine gums, patches, nasal sprays, and vapor inhalation formulations are the first-line medications for the management of nicotine cessation; however, they could not deliver high levels of nicotine to the brain as fast as cigarette smoking. E-cigarettes, an alternative to tobacco smoking, although available on the market, has been banned by the US Food and Drug Administration (FDA) due to some uncertainties of the dose, safety, and efficacy of this product. Deep lung delivery of drugs enables lower doses with an equivalent therapeutic action compared to oral or parenteral routes as the lungs have a huge surface area for drug absorption. Additionally, pulmonary drug delivery has superior efficacy, low toxicity, and rapid onset of drug action. This chapter demonstrates the health problems associated with cigarette smoking, available drugs, their dosage forms and limitations. Finally, the development of inhaled nicotine formulations as a potential anti-smoking therapeutic has been discussed.

Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.